(1S,3S(E),7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酯类和类似物
• 英文名称: (1S,3S(E),7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
• 英文别名: 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
• 化学式: C₂₇H₄₁NO₆S
• 分子量: 507.692
• InChiKey: QXRSDHAAWVKZLJ-LFIBNONCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  35
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  138
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• PROCESS FOR THE MANUFACTURE OF IXABEPILONE
  申请人：PHARMAREN , LLC

  公开号：US20180072749A1

  公开（公告）日：2018-03-15

  The invention relates to the process of manufacturing Epothilone compounds of Formulas I-IV. The process of the present invention is totally synthetic, utilizes highly pure and crystalline Epothilone B, and produces ixabepilone in high efficiency, purity, and yield.

  该发明涉及制造公式I-IV的Epothilone化合物的过程。本发明的过程完全是合成的，利用高纯度和结晶性的Epothilone B，并且高效、纯度和产量地生产出伊扎贝普隆。
• Process for the manufacture of ixabepilone
  申请人：PHARMAREN, LLC

  公开号：US10464942B2

  公开（公告）日：2019-11-05

  The invention relates to the process of manufacturing Epothilone compounds of Formulas I-IV. The process of the present invention is totally synthetic, utilizes highly pure and crystalline Epothilone B, and produces ixabepilone in high efficiency, purity, and yield.

  本发明涉及生产式 I-IV 的埃博霉素化合物的工艺。本发明的工艺是完全合成的，利用高纯度和结晶的埃博霉素 B，高效率、高纯度和高产率地生产ixabepilone。
• Epothilone derivative for the treatment of hepatoma and other cancer diseases
  申请人：Rothermel David John

  公开号：US20050282873A1

  公开（公告）日：2005-12-22

  The present invention relates to a method of treating a warm-blooded animal, especially a human, having a cancer disease selected from hepatoma; primary fallopian tube cancer; primary peritoneal cancer; breast cancer progressing after treatment with hormonal agents or radiotherapy; renal cell carcinoma progressing after treatment with a cytokine, radiotherapy and/or nephrectomy; melanoma progressing after radiotherapy; prostate cancer progressing after orchiectomy; ovarian cancer progressing after treatment with a platinum compound or radiotherapy; and colorectal cancer progressing after radiotherapy and/or treatment with oxaliplatin or irinotecan; and metastasis thereof comprising administering to said animal a therapeutically effective amount of an epothilone derivative of formula I

  本发明涉及一种治疗温血动物，特别是人类癌症疾病的方法，该癌症疾病选 自肝癌；原发性输卵管癌；原发性腹膜癌；经激素制剂或放疗治疗后进展的乳腺癌； 经细胞因子、放疗和/或肾切除术治疗后进展的肾细胞癌；经放疗治疗后进展的黑 色素瘤；经睾丸切除术治疗后进展的前列腺癌；经铂化合物或放疗治疗后进展的卵巢 癌；以及经放疗和/或治疗后进展的结直肠癌；放疗后进展的黑色素瘤；睾丸切除术后进展的前列腺癌；铂化合物或放疗后进展的卵巢癌；放疗和/或奥沙利铂或伊立替康治疗后进展的结直肠癌；及其转移，包括给所述动物施用治疗有效量的式 I 表霉素衍生物
• EPOTHILONE DERIVATIVE FOR THE TREATMENT OF HEPATOMA AND OTHER CANCER DISEASES
  申请人：NOVARTIS AG

  公开号：EP1503756B1

  公开（公告）日：2009-08-12
• USE OF EPOTHILONES IN THE TREATMENT OF NEURONAL CONNECTIVITY DEFECTS SUCH AS SCHIZOPHRENIA AND AUTISM
  申请人：INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

  公开号：EP1711230B1

  公开（公告）日：2009-01-07